Acute emesis: Moderately emetogenic chemotherapy

Supportive Care in Cancer

Volumn 19, Issue SUPPL. 1, 2011, Pages

  Herrstedt, Jørn ^g   Rapoport, Bernardo ^a   Warr, David ^b   Roila, Fausto ^c   Bria, Emilio ^d   Rittenberg, Cynthia ^e   Hesketh, Paul J ^f  

^a Medical Oncology Centre of Rosebank   (South Africa)

^b UNIVERSITY OF TORONTO   (Canada)

^c S MARIA HOSPITAL   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e Rittenberg Oncology Consulting   (United States)

^f LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^g NONE

Author keywords

Anthracycline; Chemotherapy; Cyclophosphamide; Dexamethasone; Neurokinin antagonists; Serotonin antagonists

Indexed keywords

ANTHRACYCLINE; APREPITANT; CARBOPLATIN; CASOPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; EPIRUBICIN; FOSAPREPITANT; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; IRINOTECAN; LORAZEPAM; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ACUTE EMESIS; BREAST CANCER; CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; MODERATELY EMETOGENIC CHEMOTHERAPY; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 79953319996     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0951-5     Document Type: Review

References (18)

1. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
2. Apornwirat W, Albert I, Hansen VL, Bandekar RR, Grunberg SM (2009) Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115:5807-5816
3. Grunberg SM, Dugan M, Muss H et al (2009) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17:589-594
4. Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:97-103 (Pubitemid 40558164)
5. Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F, Aprepitant Moderately Emetogenic Chemotherapy Study Group (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555 (Pubitemid 41356171)
6. Herrstedt J, Roila F, on behalf of the ESMO Guidelines Working Group (2008) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 19 (suppl 2):ii110-ii112
7. Herrstedt J, Apornwirat W, Shaharyar A et al (2009) Casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting: phase III trial results in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27:5363-5369
8. Italian Group for Antiemetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22(4):725-729
9. Johnson B, Adams L, Lu E et al (2009) Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 17(9):1177-1185
10. Kris MG, Hesketh PJ, Sommerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947 (Pubitemid 46630595)
11. Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J et al (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47 (7):834-840
12. McCrea JB, Majumdar AK, Goldberg MR et al (2003) Effects of the neurokinin antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-24 (Pubitemid 36776172)
13. NCCN Clinical Practice Guidelines in Oncology. Antiemesis V3.2009. http://www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf
14. Rapoport B, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll H-J (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423-431
15. 1- receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. Therapeutic Clin Risk Manag 5:375-384
16. Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a doubleblind, double-dummy, randomized, comparative phase III trial. Lancet Oncol 10:115-124
17. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830 (Pubitemid 46179473)
18. Yeo W, Mo FKF, Suen JJS et al (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113:529-535